Home

LILLY & Co ELI

CIK 59478 · Director, Chairman and CEO · last filed 2023-08-14

LILLY & Co ELI is a Director, Chairman and CEO who has filed 26 SEC Form 4 insider transactions across 10 companies since 2010. The most recent filing shows the insider bought $51.3M of SGTX on Aug 14, 2023. Across all open-market trades the lifetime net is +$1.57B, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $2.92B across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$2.92B

Companies

10

Total Filings

26

Lifetime Open-Market Net

$1.57B

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Sigilon Therapeutics, Inc. (SGTX) Delisted 10%+ Owner 100 $22.47 $2.2K $56.68M 2 2023-08-14
RNA 10%+ Owner 2,169,396 $13.19 $28.61M $0 1 2020-06-16
DERM 10%+ Owner 100 $6.62 $662 $1.53B 1 2020-02-20
Elanco Animal Health Inc (ELANw) Delisted 10%+ Owner 0 — — $0 1 2019-03-11
ZYME 10%+ Owner 1,827,101 $24.15 $44.12M -$15.35M 14 2019-02-06
CYPHERPUNK TECHNOLOGIES INC. (LPTX) Delisted 10%+ Owner — $1.56 — $0 1 2018-08-13
CoLucid Pharmaceuticals, Inc. (CLCD) Delisted 10%+ Owner 100 — — $0 1 2017-03-01
Spyre Therapeutics, Inc. (AGLE) Delisted 10%+ Owner 2,568,543 $12.01 $30.85M $5.00M 1 2016-04-14
Receptos, Inc. (RCPT) Delisted 10%+ Owner 2,081,210 — — $6.00M 1 2013-11-21
UTHR 10%+ Owner 5,251,394 $542.66 $2.85B -$12.96M 3 2011-07-06

Recent Filings

26 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2023-08-14 Sigilon Therapeutics, Inc. (SGTX) Delisted Buy (P) +3,436,986 $51.28M EDGAR
2020-12-10 Sigilon Therapeutics, Inc. (SGTX) Delisted Mixed +2,744,443 $5.40M EDGAR
2020-06-16 RNA Conv (C) +2,169,396 $0 EDGAR
2020-02-20 DERM Buy (P) +81,852,050 $1.53B EDGAR
2019-03-11 Elanco Animal Health Inc (ELANw) Delisted Disp (D) −293,290,000 $0 EDGAR
2019-02-06 ZYME — — $0 EDGAR
2019-02-04 ZYME Sell (S) −250,000 -$4.00M EDGAR
2018-11-08 ZYME Sell (S) −700,000 -$9.80M EDGAR
2018-09-26 ZYME Sell (S) −2,027 -$33.2K EDGAR
2018-09-20 ZYME Sell (S) −6,870 -$100.0K EDGAR
Showing 1–10 of 26
Page 1 of 3
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.